Spectral AI Announces Total U.S. and International Patent Portfolio Now Stands at 26 Granted Patents and 38 Pending Applications in Support of its AI-Driven DeepView System
Spectral AI (Nasdaq: MDAI) has announced a 30% increase in its patent portfolio, strengthening its proprietary AI-driven DeepView System for wound assessment. The company now holds 26 granted patents (12 U.S. and 14 international) and 38 pending applications worldwide. These patents cover various aspects of the DeepView System, including tissue classification, machine learning, and high-precision imaging.
CEO Peter M. Carlson emphasized the novel nature of the DeepView System and its ability to provide immediate, objective wound healing assessments. The company plans to commence product commercialization initiatives in late 2024 through 2026. Board member Erich Spangenberg, a recognized IP expert and the company's largest shareholder, is actively supporting management in building a strong intellectual property position.
Spectral AI (Nasdaq: MDAI) ha annunciato un aumento del 30% del proprio portafoglio brevettuale, rafforzando il suo sistema proprietario DeepView basato su intelligenza artificiale per la valutazione delle ferite. L'azienda detiene ora 26 brevetti concessi (12 negli Stati Uniti e 14 internazionali) e 38 domande pendenti in tutto il mondo. Questi brevetti coprono vari aspetti del sistema DeepView, inclusa la classificazione dei tessuti, l'apprendimento automatico e l'imaging ad alta precisione.
Il CEO Peter M. Carlson ha sottolineato la novità del sistema DeepView e la sua capacità di fornire valutazioni immediate e obiettive della guarigione delle ferite. L'azienda prevede di avviare iniziative di commercializzazione dei prodotti tra la fine del 2024 e il 2026. Il membro del consiglio Erich Spangenberg, un riconosciuto esperto di proprietà intellettuale e il maggior azionista della società, sta attivamente supportando la direzione nella costruzione di una solida posizione di proprietà intellettuale.
Spectral AI (Nasdaq: MDAI) ha anunciado un aumento del 30 % en su cartera de patentes, fortaleciendo su sistema DeepView impulsado por IA para la evaluación de heridas. La compañía ahora posee 26 patentes concedidas (12 en EE. UU. y 14 internacionales) y 38 solicitudes pendientes en todo el mundo. Estas patentes cubren varios aspectos del sistema DeepView, incluyendo la clasificación de tejidos, el aprendizaje automático y la imagenología de alta precisión.
El CEO Peter M. Carlson enfatizó la naturaleza innovadora del sistema DeepView y su capacidad para proporcionar evaluaciones objetivas e inmediatas de la cicatrización de heridas. La compañía planea iniciar iniciativas de comercialización de productos entre finales de 2024 y 2026. El miembro de la junta Erich Spangenberg, un reconocido experto en propiedad intelectual y el mayor accionista de la empresa, está apoyando activamente a la gerencia para construir una sólida posición de propiedad intelectual.
스펙트럴 AI (Nasdaq: MDAI)는 특허 포트폴리오를 30% 증가시켰다고 발표했습니다. 이는 상처 평가를 위한 AI 기반의 독자적인 DeepView 시스템을 강화하는 것입니다. 이 회사는 현재 26개의 특허를 보유하고 있습니다 (12개의 미국 특허와 14개의 국제 특허) 및 전 세계적으로 38개의 대기 중 신청서를 보유하고 있습니다. 이 특허는 조직 분류, 기계 학습 및 고정밀 이미징을 포함한 DeepView 시스템의 다양한 측면을 포괄합니다.
CEO인 Peter M. Carlson은 DeepView 시스템의 혁신적인 성격과 즉각적이고 객관적인 상처 치유 평가를 제공할 수 있는 능력을 강조했습니다. 이 회사는 2024년 말부터 2026년까지 제품 상용화 계획을 세우고 있습니다. 이 회사의 최대 주주인 Erich Spangenberg 이사는 지식 재산권 전문가로서 경영진이 강력한 지적 재산 위치를 구축하는 데 적극 지원하고 있습니다.
Spectral AI (Nasdaq: MDAI) a annoncé une augmentation de 30 % de son portefeuille de brevets, renforçant ainsi son système DeepView axé sur l'IA pour l'évaluation des plaies. L'entreprise détient désormais 26 brevets accordés (12 aux États-Unis et 14 internationaux) et 38 demandes en cours dans le monde entier. Ces brevets couvrent divers aspects du système DeepView, y compris la classification des tissus, l'apprentissage automatique et l'imagerie haute précision.
Le PDG Peter M. Carlson a souligné le caractère novateur du système DeepView et sa capacité à fournir des évaluations immédiates et objectives de la guérison des plaies. L'entreprise prévoit de commencer les initiatives de commercialisation des produits entre la fin de 2024 et 2026. Membre du conseil, Erich Spangenberg, un expert reconnu en propriété intellectuelle et le plus grand actionnaire de la société, soutient activement la direction dans la construction d'une position solide en matière de propriété intellectuelle.
Spectral AI (Nasdaq: MDAI) hat eine Steigerung des Patentportfolios um 30 % angekündigt, wodurch das proprietäre AI-gesteuerte DeepView-System zur Wundbewertung gestärkt wird. Das Unternehmen hält nun 26 erteilte Patente (12 in den USA und 14 international) und 38 ausstehende Anträge weltweit. Diese Patente decken verschiedene Aspekte des DeepView-Systems ab, darunter Gewebe-Klassifikation, maschinelles Lernen und hochpräzise Bildgebung.
CEO Peter M. Carlson hob die neuartige Natur des DeepView-Systems und dessen Fähigkeit hervor, sofortige, objektive Bewertungen der Wundheilung zu liefern. Das Unternehmen plant, zwischen Ende 2024 und 2026 mit der Produktkommerzialisierung zu beginnen. Vorstandsmitglied Erich Spangenberg, ein anerkannter Experte für geistiges Eigentum und größter Aktionär des Unternehmens, unterstützt aktiv das Management beim Aufbau einer starken Position im Bereich geistiges Eigentum.
- 30% increase in patent portfolio, strengthening IP protection
- Total granted patents increased to 26 from 20 in six months
- 38 additional pending patent applications worldwide
- Patents cover key aspects of the DeepView System platform
- Product commercialization initiatives planned for late 2024 through 2026
- None.
The expansion of Spectral AI's patent portfolio significantly bolsters the company’s intellectual property (IP) assets. In the tech industry, particularly in AI and medical diagnostics, strong IP protection is critical. These patents cover advanced technologies such as multi-spectral imaging and machine learning, which are at the core of Spectral AI's DeepView System. This not only protects the company's innovations from competitors but also enhances its competitive edge and potential market value. The increase in patents also signals to investors that Spectral AI is at the forefront of technological advancements, reducing risks associated with innovation theft and potentially leading to higher long-term returns.
The fact that Spectral AI has expanded its patent portfolio is an important signal to the market. From an investment perspective, a robust patent portfolio can be a key indicator of future earnings potential. It showcases the company’s dedication to innovation and its commitment to maintaining a competitive advantage. This move could attract strategic partnerships, licensing deals and potential acquirers, which can drive up the stock price. Furthermore, as Spectral AI prepares for product commercialization, these patents could help justify premium pricing strategies and broaden their market reach, making the company an attractive investment both in the short and long term.
From a financial viewpoint, the growth of Spectral AI's patent portfolio could be seen as a positive development. Patents are intangible assets that can significantly increase the company's valuation. They also serve as a barrier to entry for competitors, potentially leading to a more monopolistic position in the market. This could result in higher profit margins and robust revenue streams as the company begins commercializing its products. Additionally, the implied focus on product development and innovation may lead to improved operational efficiencies and cost reductions over time, further enhancing profitability and shareholder value.
DALLAS, July 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a
Total patents granted to the Company increased to 26 through July 8, 2024 from 20 at December 31, 2023, consisting of 12 U.S. and 14 international patents. These patents cover various aspects of the Company’s DeepView System platform, including, but not limited to, tissue classification based on multi-spectral imaging, machine learning and healthcare metrics, wound assessments based on multi-spectral imaging, optical biomarkers, machine learning and high precision imaging with multiplexed illumination.
The Company continues to protect its data and processes with an additional 38 pending patent applications worldwide, consisting of seven pending U.S. patents and 31 pending international patents. The patents encompass nine distinct patent families.
“These newly granted patents highlight the novel nature of our DeepView System platform and its ability to deliver an immediate, objective, and grounded assessment of a wound’s healing potential,” said Peter M. Carslon, Chief Executive Officer. “The DeepView System platform reflects years of significant investment in product development and our team is continuing to enhance the underlying technology. Together with our trademarks and trade secrets, these intellectual property assets are keys to our success and will serve as a foundation for our planned product commercialization initiatives set to commence in late 2024 and continuing through 2026.”
“We remain diligent in protecting and enhancing our proprietary technologies,” said Erich Spangenberg, Spectral AI board member, a globally recognized IP expert, and the Company’s largest shareholder. “I am actively engaged in supporting management as it builds and maintains a world-class moat around these critical assets.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to change the current standard of care, the DeepView System is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan
Managing Director
dsullivan@equityny.com
Conor Rodriguez
Analyst
crodriguez@equityny.com
FAQ
How many patents does Spectral AI (MDAI) currently hold?
What is the percentage increase in Spectral AI's (MDAI) patent portfolio?
What technology does Spectral AI's (MDAI) DeepView System use?
When does Spectral AI (MDAI) plan to start commercializing its products?
